上海醫藥(02607.HK)向HUYABIO授予小分子化學藥SPH6162海外權益許可
上海醫藥(02607.HK)宣布,與美國新藥開發公司HUYABIO簽署正式協議,向其授出抗腫瘤新藥SPH6162的海外權益許可,HUYABIO擬支付最高不超過2.925億美元的里程碑付款,另加3%至6%的銷售提成,以獲得上海醫藥抗腫瘤新藥SPH6162在中國大陸、香港、澳門、台灣區域外的獨家產品開發、生產和銷售的授權以及再許可的權利。
另外,雙方還預計成立聯合開發委員會,負責協調全球產品的開發以及商業化事宜。公司表示,此為上海醫藥的首個海外許可項目,是標誌著公司研發創新能力顯著進步的里程碑。
SPH6162是由上海醫藥中央研究院自主研發的小分子化學藥,目前具有高度潛力開發為放化療藥物的增敏劑或針對某類突變腫瘤細胞的合成致死藥物,處於候選化合物階段,已提交兩款國際專利申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.